Toru Takahashi

Toru Takahashi

Auto-generated profile, based on publicly available information

Toru Takahashi

Yamaguchi Grand Medical Center

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2013 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
TTToru Takahashi
Toru Takahashi
KMKen Maeda
Ken Maeda
TSTadaki Suzuki
Tadaki Suzuki
AIAki Ishido
Aki Ishido
TSToru Shigeoka
Toru Shigeoka
MSMasayuki Saijo
Masayuki Saijo
Background. Severe fever with thrombocytopenia syndrome (SFTS) is caused by SFTS virus (SFTSV), a novel bunyavirus reported to be endemic in central and northeastern China. This article describes the first identified patient with SFTS and a retrospective study on SFTS in Japan. Methods. Virologic and pathologic examinations were performed on the patient's samples. Laboratory diagnosis of SFTS was made by isolation/genome amplification and/or the detection of anti-SFTSV immunoglobulin G antibody in sera. Physicians were alerted to the initial diagnosis and asked whether they had previously treated patients with symptoms similar to those of SFTS. Results. A female patient who died in 2012 received a diagnosis of SFTS. Ten additional patients with SFTS were then retrospectively identified. All patients were aged ≥50 years and lived in western Japan. Six cases were fatal. The ratio of males to females was 8:3. SFTSV was isolated from 8 patients. Phylogenetic analyses indicated that all of the Japanese SFTSV isolates formed a genotype independent to those from China. Most patients showed symptoms due to hemorrhage, possibly because of disseminated intravascular coagulation and/or hemophagocytosis. Conclusions. SFTS has been endemic to Japan, and SFTSV has been circulating naturally within the country.

11 December 2003 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
TTToru Takahashi
Toru Takahashi
TYToshiaki Yujiri
Toshiaki Yujiri
KSKenji Shinohara
Kenji Shinohara
YIYusuke Inoue
Yusuke Inoue
YSYutaka Sato
Yutaka Sato
YTYukio Tanizawa
Yukio Tanizawa
Summary: The eradication of Helicobacter pylori often leads to platelet recovery in patients with chronic idiopathic thrombocytopenic purpura (cITP). Although this clinical observation suggests the involvement of H. pylori, little is known about the pathogenesis of cITP. We initially examined the effect of H. pylori eradication on platelet counts in 20 adult Japanese cITP patients. Then, using platelet eluates as the probe in immunoblot analyses, we examined the role of molecular mimicry in the pathogenesis of cITP. Helicobacter pylori infection was detected in 75% (15 of 20) of cITP patients. Eradication was achieved in 13 (87%) of the H. pylori‐positive patients, seven (54%) of which showed increased platelet counts within the 4 months following treatment. Completely responsive patients also showed significant declines in platelet‐associated immunoglobulin G (PAIgG) levels. Platelet eluates from 12 (nine H. pylori‐positive and three H. pylori‐negative) patients recognized H. pylori cytotoxin‐associated gene A (CagA) protein, and in three completely responsive patients, levels of anti‐CagA antibody in platelet eluates declined after eradication therapy. Cross‐reactivity between PAIgG and H. pylori CagA protein suggests that molecular mimicry by CagA plays a key role in the pathogenesis of a subset of cITP patients.

22 February 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
KSKoichiro Suemori
Koichiro Suemori
MSMasayuki Saijo
Masayuki Saijo
AYAtsushi Yamanaka
Atsushi Yamanaka
DHDaisuke Himeji
Daisuke Himeji
MKMasafumi Kawamura
Masafumi Kawamura
MYMasaki Yasukawa
Masaki Yasukawa
Severe fever with thrombocytopenia syndrome (SFTS) is a bunyavirus infection with high mortality. Favipiravir has shown effectiveness in preventing and treating SFTS virus (SFTSV) infection in animal models. A multicenter non-randomized, uncontrolled single arm trial was conducted to collect data on the safety and the effectiveness of favipiravir in treatment of SFTS patients. All participants received favipiravir orally (first-day loading dose of 1800 mg twice a day followed by 800 mg twice a day for 7–14 days in total). SFTSV RT-PCR and biochemistry tests were performed at designated time points. Outcomes were 28-day mortality, clinical improvement, viral load evolution, and adverse events (AEs). Twenty-six patients were enrolled, of whom 23 were analyzed. Four of these 23 patients died of multi-organ failure within one week (28-day mortality rate: 17.3%). Oral favipiravir was well tolerated in the surviving patients. AEs (abnormal hepatic function and insomnia) occurred in about 20% of the patients. Clinical symptoms improved in all patients who survived from a median of day 2 to day10. SFTSV RNA levels in the patients who died were significantly higher than those in the survivors (p = 0.0029). No viral genomes were detectable in the surviving patients a median of 8 days after favipiravir administration. The 28-day mortality rate in this study was lower than those of the previous studies in Japan. The high frequency of hepatic dysfunction as an AE was observed. However, it was unclear whether this was merely a side effect of favipiravir, because liver disorders are commonly seen in SFTS patients. The results of this trial support the effectiveness of favipiravir for patients with SFTS. Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne virus infection caused by Dabie bandavirus (formerly SFTS virus, SFTSV), which belongs to the Bandavirus genus of the Phenuiviridae family. The case fatality rate of patients with SFTS is high ranging from 16.2% to 47%. SFTS is endemic to East and Southeast Asia. Favipiravir, an antiviral agent with an inhibitory activity on the RNA-dependent RNA polymerase, inhibited replication of SFTSV in vitro and in vivo. It was suggested that favipiravir treatment lowered the case fatality rate of patients with SFTS by approximately 10% in comparison with those reported so far through epidemiological survey in Japan. People living in the SFTS-endemic regions can not escape from the risk of being infected with SFTSV. Favipiravir might be an effective drug for treatment of patients with SFTS and reduces the mortality and morbidity of patients with SFTS.

13 December 1990 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
NIN Ito
N Ito
TMT Matsuda
T Matsuda
YKY Kakehi
Y Kakehi
ETE Takeuchi
E Takeuchi
TTT Takahashi
T Takahashi
OYO Yoshida
O Yoshida
We report the production of granulocyte colony-stimulating factor (G-CSF) in a patient with bladder cancer, which was confirmed by immunofluorescence staining of tumor tissue. A 48-year-old man died of bladder cancer (transitional-cell carcinoma, grade 3). An autopsy revealed multiple metastases to the liver, lungs, vertebrae, prostate, and cerebellum. The patient had had marked leukocytosis (maximum, 141.0×109 per liter), first observed three months before his death, but no increase in the number of immature granulocytes or eosinophils. The serum G-CSF level, measured by enzyme immunoassay,1 was 2359 ng per liter (normal, <30) one month before his death. He had received cisplatin-based chemotherapy for nine months and irradiation of the right ilium and acetabulum. He had not received G-CSF at any time. On indirect immunofluorescence testing with a murine monoclonal antibody against human G-CSF, G-CSF was found in most of the cancer cells in the primary tumor and in the lesions that had metastasized to the liver and lungs ( Fig. 1 ).


4 February 2019 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
TTToru Takahashi
Toru Takahashi
TSTadaki Suzuki
Tadaki Suzuki
SHShunsuke Hiroshige
Shunsuke Hiroshige
SNShota Nouno
Shota Nouno
TMTakuro Matsumura
Takuro Matsumura
HHHideki Hasegawa
Hideki Hasegawa
Atypical lymphocytes in the peripheral blood in patients with severe fever with thrombocytopenia syndrome ( SFTS) have not been well examined. In this study, we analyzed counts and characteristics of atypical lymphocytes in 7 patients with SFTS. Atypical lymphocytes resembled plasma cells morphologically and appeared in the peripheral blood of all patients 4-8 days after onset of disease. Among these lymphocytes flow cytometry showed a CD19(+)CD38(+)CD138(-/+) phenotype, and immunohistochemical staining revealed a CD79a(+)CD38(+)CD138(-/+)CD27(+) phenotype. From our observations, atypical lymphocytes transiently that appeared in the peripheral blood during the acute phase of SFTS were considered to be plasmablasts.